N
New Radiomedicine Technology
New Radiomedicine Technology is a research, production and sales company
About New Radiomedicine Technology
Chengdu New Radiomedicine Technology Co., Ltd. (NRT) is a biopharmaceutical company established in 2016, concentrating on the development and commercialization of radiopharmaceuticals. It was founded by Jiming Cai, Jihui Qian, and Maoliang Li, who are described as veterans in the nuclear medicine technology field. The company is headquartered in Chengdu, China, a significant hub for the nuclear industry, and has expanded its presence with four domestic subsidiaries and international offices in San Diego, USA, and Melbourne, Australia.
NRT's business model encompasses the entire value chain, from the production of medical isotopes to the innovation, research, and development of radiopharmaceutical drugs. The company serves the oncology market by providing hospitals and medical institutions with drugs for both the diagnosis and treatment of various cancers. Its revenue generation is supported by venture capital funding, with a Series C funding round in March 2024 raising over 300 million yuan ($41.8M USD) to advance its research and production capabilities. NRT also provides Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services.
The company's core offering is a portfolio of radiopharmaceuticals, which are drugs containing radioactive elements used for medical imaging and therapy. A key area of focus is Radioligand Therapy (RLT), a targeted approach that delivers cytotoxic radiation directly to cancer cells by binding to specific biomarkers, thereby minimizing damage to healthy tissue. NRT's product pipeline includes TareSphere™, Yttrium-90 carbon microspheres for treating cancers with minimally invasive procedures, which are currently in late-stage clinical trials. It has also developed proprietary generator systems, the Galliator™ (Gallium-68) and Techneator™ (Technetium-99), and produces key medical isotopes like Lutetium-177. To support its production, NRT is installing a high-capacity Cyclone® IKON cyclotron, expected to be operational by 2025, which will produce a range of isotopes crucial for theranostics.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Apr 2026 | $138M | $550M | Cornerstone Capital · Yuekai Securities · Nanjing Gaoke · Sichuan Venture Capital | ↗ |
| SERIES DOther financing | Oct 2025 | $110M | $440M | Zhongqi Private Equity Fund Management (Hainan) · CNNC Industry Fund · Guangdong Hengjian Investment · PICC Capital Investment Management | ↗ |
Growth signals
Latest recorded traffic for New Radiomedicine Technology is 1.6K monthly website visits, up 5233.3% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
New Radiomedicine Technology in the Chengdu ecosystem
The New Radiomedicine Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
BTG
Series B and later21 investors entered at this stage
- CCChengdu Science and Technology Venture Capital
Star Capital- XCXinjun Capital
- SMSichuan Innovation Development Investment Management
- CFChengdu Biocity Fund
- HKHuaxing Kangping
PICC Capital Investment Management
Shenzhen Capital Group- Z(Zhongqi Private Equity Fund Management (Hainan)
- CFCNNC Industry Fund
- GIGuangdong Hengjian Investment
AstraZeneca Pharmaceutical
Chasing FinancialShanghai Science and Technology Innovation Center
Cornerstone Capital- YSYuekai Securities
- NGNanjing Gaoke
Sichuan Venture Capital
Shanghai Guoxin Venture Capital- PCPudong Venture Capital
- YCYifeng Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about New Radiomedicine Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See New Radiomedicine Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









